LA JOLLA, Calif., May 3, 2021 /PRNewswire/ -- Avidity
Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company
pioneering a new class of oligonucleotide-based therapies called
Antibody Oligonucleotide Conjugates (AOCs™), today announced that
it will host a virtual investor and analyst event focused on the
company's AOC platform on Wednesday, May 19,
2021, from 8:00 a.m. to 10:00 a.m.
PT/11:00 a.m. to 1:00 p.m.
ET. This event is the first in a series of investor
and analyst events that the company plans to host in
2021.
The May 19th event will
feature a panel discussion with Phillip D.
Zamore, Ph.D., Chair of the RNA Therapeutics Institute at
UMASS, Steven
F. Dowdy, Ph.D., Professor of Cellular and Molecular
Medicine at UCSD, and Art Levin,
Ph.D., Avidity's Chief Scientific Officer. The Avidity
management team and Drs. Zamore and Dowdy will host a question and
answer session following the panel.
The event will also feature a presentation from Dr. Levin who
will provide an overview of the company's AOC platform and the
translation of the platform into a pipeline of programs.
Background on Drs. Zamore and Dowdy:
Phillip D. Zamore, Ph.D., the
Gretchen Stone Cook Professor of Biomedical Sciences, Professor of
Biochemistry and Molecular Pharmacology, and Investigator of the
Howard Hughes Medical Institute, is Chair of the RNA Therapeutics
Institute, which was established at the University of Massachusetts Medical School in 2009.
He has a long history in RNA-targeting therapeutics and has been
associated with the leading companies in the field. Dr. Zamore
received his A.B. and Ph.D. degrees in Biochemistry and Molecular
Biology from Harvard University. He
then pursued postdoctoral studies at MIT and the Whitehead Institute for Biomedical
Research.
Steven F. Dowdy, Ph.D., is a
professor in the Department of Cellular & Molecular Medicine at
the University of California San Diego
School of Medicine. His research focuses on the delivery of novel
therapeutics, especially RNAi therapies, into cells. He has been
involved in multiple RNA biotech startups and currently sits on
five Scientific Advisory Boards. Dr. Dowdy received his Ph.D. in
Molecular Genetics from the University of
California Irvine and performed his postdoctoral fellowship
at MIT and the Whitehead Institute for
Biomedical Research. Dr. Dowdy was a Howard Hughes Medical
Institute Investigator for 18 years.
Video Webcast Information
A live video webcast of the event will be available on the
"Events and Presentations" page in the "Investors" section of
Avidity's website at
https://aviditybiosciences.investorroom.com/events-and-presentations.
A replay of the webcast will be archived on Avidity's website
following the event.
About Avidity Biosciences
Avidity Biosciences, Inc. is driven to change lives with a new
class of therapies called Antibody Oligonucleotide Conjugates
(AOCs) that are designed to overcome current limitations of
oligonucleotide therapies in order to treat a wide range of serious
diseases. Avidity's proprietary AOC platform combines the tissue
selectivity of monoclonal antibodies and the precision of
oligonucleotide therapies to access previously undruggable tissue
and cell types and more effectively target underlying genetic
drivers of diseases. Avidity's lead product candidate, AOC 1001, is
designed to treat myotonic dystrophy type 1, and its other muscle
programs are focused on the treatment of Duchenne muscular
dystrophy, facioscapulohumeral muscular dystrophy, Pompe disease
and muscle atrophy. In addition to its muscle franchise, Avidity
has research efforts focused on immune, cardiac and other cell
types.
Avidity is headquartered in La Jolla, CA. For more
information about Avidity's science, pipeline and people,
please visit www.aviditybiosciences.com and engage with
Avidity on LinkedIn.
Contacts:
Company:
Mike MacLean
(858) 401-7900
mikemaclean@aviditybio.com
Media and Investors:
Amy Conrad
Juniper Point
(858) 366-3243
amy@juniper-point.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/avidity-biosciences-to-host-virtual-investor-and-analyst-event-on-may-19-2021-301282130.html
SOURCE Avidity Biosciences, Inc.